ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
NCT ID: NCT05653063
Last Updated: 2024-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
990 participants
OBSERVATIONAL
2023-12-07
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Human Versus Machine Comparison Study
NCT06035653
A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
NCT06686459
Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI
NCT05565313
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
NCT06995664
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
NCT05802186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A web-based artificial intelligence (AI) auto-planning tool
The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.
In this study patients will not be treated with the AI tool but the manual plan created by the local teams.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy.
3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy.
4. Mental capacity to understand and consent to participate in the study.
5. Patients aged ≥18years.
Exclusion Criteria
2. Patients receiving palliative radiotherapy
3. Patients aged \< 18years.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Rising Tide Foundation
OTHER
Medical Research Council
OTHER_GOV
Tata Memorial Hospital
OTHER_GOV
Tata Memorial Centre
OTHER
University of Stellenbosch
OTHER
King Hussein Cancer Center
OTHER
University of Malaya
OTHER
University Ghent
OTHER
M.D. Anderson Cancer Center
OTHER
Mount Vernon Cancer Centre at Mount Vernon Hospital
OTHER
University of Cape Town
OTHER
National Cancer Institute (NCI)
NIH
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tata Medical Centre
Kolkata, , India
Tata Memorial Hospital
Mumbai, , India
King Hussein Cancer Center
Amman, , Jordan
University of Malaya Medical Center
Kuala Lumpur, , Malaysia
Groote Schuur Hospital
Cape Town, , South Africa
Tygerberg Hospital
Stellenbosch, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr Mallick
Role: primary
Dr Ghosh-Laskar
Role: primary
Dr Mohamad
Role: primary
Dr Malik
Role: primary
Prof Parkes
Role: primary
Dr Trauernicht
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10678756
Identifier Type: OTHER
Identifier Source: secondary_id
ARCHERY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.